|
ES2248581T3
(es)
|
2001-03-12 |
2006-03-16 |
Intercept Pharmaceuticals, Inc. |
Esteroides como agonistas de fxr.
|
|
GB0302094D0
(en)
|
2003-01-29 |
2003-02-26 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
US9498484B2
(en)
|
2004-03-12 |
2016-11-22 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
US7618956B2
(en)
|
2005-05-31 |
2009-11-17 |
The Gillette Company |
Reduction of hair growth
|
|
US7705028B2
(en)
|
2005-12-19 |
2010-04-27 |
Glaxosmithkline Llc |
Farnesoid X receptor agonists
|
|
WO2007092751A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Eli Lilly And Company |
Compounds and methods for modulating fx-receptors
|
|
WO2007140183A1
(en)
*
|
2006-05-24 |
2007-12-06 |
Eli Lilly And Company |
Fxr agonists
|
|
PE20080259A1
(es)
|
2006-05-24 |
2008-04-10 |
Lilly Co Eli |
Compuestos y metodos para modular fxr
|
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
|
EP1894928A1
(en)
*
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
|
EP1894924A1
(en)
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
WO2008091540A2
(en)
|
2007-01-19 |
2008-07-31 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as tgr5 modulators and methods of use thereof
|
|
CN101977505A
(zh)
*
|
2007-06-13 |
2011-02-16 |
葛兰素史密丝克莱恩有限责任公司 |
类法尼醇x受体激动剂
|
|
AU2008270784A1
(en)
*
|
2007-07-02 |
2009-01-08 |
Glaxosmithkline Llc |
Farnesoid X receptor agonists
|
|
TW200906823A
(en)
*
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
WO2009012400A2
(en)
*
|
2007-07-19 |
2009-01-22 |
University Of Southern California |
Orally administered peptides to improve or prevent hepatic fibrosis
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
AU2008333320B2
(en)
|
2007-12-04 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Isoxazolo-pyrazine derivatives
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
US20100324075A1
(en)
*
|
2007-12-21 |
2010-12-23 |
University Of Cincinnati |
Therapeutic use of carboxyl ester lipase inhibitors
|
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
|
US8796249B2
(en)
|
2008-07-30 |
2014-08-05 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
MX2011004125A
(es)
*
|
2008-10-21 |
2011-05-19 |
Metabolex Inc |
Agonistas del receptor gpr120 de arilo y usos de los mismos.
|
|
KR101667436B1
(ko)
|
2008-11-19 |
2016-10-18 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ５ 조절제 및 그의 사용 방법
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8227461B2
(en)
|
2009-04-30 |
2012-07-24 |
Hoffmann-La Roche Inc. |
Isoxazoles
|
|
KR101367012B1
(ko)
|
2009-05-05 |
2014-03-14 |
에프. 호프만-라 로슈 아게 |
이속사졸-피리딘 유도체
|
|
JP6026273B2
(ja)
|
2009-05-05 |
2016-11-16 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
イソオキサゾール−ピリダジン誘導体
|
|
US8178522B2
(en)
|
2009-05-05 |
2012-05-15 |
Hoffmann-La Roche Inc. |
Thiazoles
|
|
BRPI1014454A2
(pt)
|
2009-05-05 |
2016-04-05 |
Hoffmann La Roche |
derivados de isoxazol-pirazol
|
|
KR101354416B1
(ko)
|
2009-05-07 |
2014-02-19 |
에프. 호프만-라 로슈 아게 |
감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
NZ604018A
(en)
|
2010-06-07 |
2015-02-27 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
EA032347B1
(ru)
|
2012-06-19 |
2019-05-31 |
Интерсепт Фармасьютикалз, Инк. |
Получение, применение и твердые формы обетихолевой кислоты
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
AU2014320463B2
(en)
|
2013-09-11 |
2018-08-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
|
|
US10301268B2
(en)
*
|
2014-03-13 |
2019-05-28 |
The Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
RS62110B1
(sr)
|
2015-03-31 |
2021-08-31 |
Enanta Pharm Inc |
Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
|
|
JP6941109B2
(ja)
*
|
2016-02-22 |
2021-09-29 |
ノバルティス アーゲー |
Ｆｘｒアゴニストを使用するための方法
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10138228B2
(en)
|
2016-05-18 |
2018-11-27 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use therof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
CA2968836A1
(en)
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
CA3026512A1
(en)
|
2016-06-13 |
2017-12-21 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
US10414048B2
(en)
|
2016-09-14 |
2019-09-17 |
Faro Technologies, Inc. |
Noncontact safety sensor and method of operation
|
|
EP3523298A4
(en)
|
2016-10-04 |
2020-06-24 |
Enanta Pharmaceuticals, Inc. |
ISOXAZOLANALOGA AS FXR AGONISTS AND METHOD FOR USE THEREOF
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2018153933A1
(en)
|
2017-02-21 |
2018-08-30 |
Genfit |
Combination of a ppar agonist with a fxr agonist
|
|
EP4122464B1
(en)
|
2017-03-28 |
2024-05-15 |
Gilead Sciences, Inc. |
Therapeutic combinations for treating liver diseases
|
|
CN110944635A
(zh)
|
2017-03-30 |
2020-03-31 |
国家医疗保健研究所 |
用于减少附加体病毒的持久性和表达的方法和药物组合物
|
|
AU2018252880B2
(en)
*
|
2017-04-12 |
2020-09-03 |
Il Dong Pharmaceutical Co., Ltd. |
An isoxazole derivatives as nuclear receptor agonists and used thereof
|
|
KR20200081435A
(ko)
|
2017-11-01 |
2020-07-07 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
|
|
US11286252B2
(en)
|
2017-11-01 |
2022-03-29 |
Bristol-Myers Squibb Company |
Alkene spirocyclic compounds as farnesoid X receptor modulators
|
|
KR20200081436A
(ko)
|
2017-11-01 |
2020-07-07 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 알켄 화합물
|
|
WO2019118571A1
(en)
|
2017-12-12 |
2019-06-20 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
IT201800007265A1
(it)
*
|
2018-07-17 |
2020-01-17 |
|
Isossazoli come agonisti del recettore fxr
|
|
EP4360632A3
(en)
|
2019-01-15 |
2024-06-19 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
EP3927683A1
(en)
|
2019-02-19 |
2021-12-29 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
US11555032B2
(en)
|
2019-05-13 |
2023-01-17 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US20220227745A1
(en)
*
|
2019-06-14 |
2022-07-21 |
Nanjing Ruijie Pharma Tech Co., Ltd. |
Compounds For Modulating FXR
|
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
|
EP4048399A4
(en)
*
|
2019-10-24 |
2023-10-25 |
ONO Pharmaceutical Co., Ltd. |
INHIBITORS OF THE FUNCTION OF TREK CHANNELS (K+ CHANNELS ASSOCIATED WITH TWIK)
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists to treat hepatitis d virus infection
|
|
US20240100125A1
(en)
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
|
TW202308629A
(zh)
|
2021-04-28 |
2023-03-01 |
法商Ｅｎｙｏ製藥公司 |
使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
|
|
WO2023090858A1
(ko)
*
|
2021-11-17 |
2023-05-25 |
일동제약(주) |
아이속사졸 유도체의 제조 방법 및 그의 중간체
|
